Hantavirus Research

As CEO of Ichor Biologics, I lead efforts to develop antibody-based therapeutics for hantavirus infections, a for-profit biotechnology start up based in New York City. Hantavirus therapeutics is a primary program for Ichor Biologics, which reflects my ongoing commitment to translating scientific discovery into life-saving treatments. Our work at Ichor has provided critical insights into humoral immune responses, antibody functions, and immune pathogenesis, guiding therapeutic advancements against this life-threatening virus.


Key Areas of Focus:

Development of therapeutic Antibodies to treat Hantavirus Infections: Our work has developed and characterized monoclonal antibodies with protective efficacy against Andes orthohantavirus, contributing to Ichor Biologics’ therapeutic pipeline.

Immune Mechanisms in Hantavirus Pathogenesis: This collaborative research has identified antibody response patterns and cytokine profiles linked to severe disease, informing biomarker discovery for patient outcomes.

T Cell-Driven Pathogenesis: This collaborative work has investigated how hantavirus glycoproteins influence T cell phenotypes, enhancing understanding of immune dysregulation in infection.


Selected Publications:

Williamson, B., et al. (2021). Monoclonal antibody efficacy against late-stage Andes orthohantavirus. Emerging Infectious Diseases.

Garrido, J.L., et al. (2018). Protective recombinant human monoclonal antibodies against lethal Andes hantavirus. Science Translational Medicine.

Salinas, T., et al. (2021). Cytokine profiles and antibody responses in Choclo Orthohantavirus infection. Frontiers in Immunology. (Co-senior author)

Saavedra, F., et al. (2020). Treg cell phenotype induced by Andes hantavirus glycoproteins. Frontiers in Cellular and Infection Microbiology.

Through Ichor Biologics, I help to drive innovation in antibody-based therapies for hantavirus, accelerating the path from discovery to clinical impact.